Literature DB >> 11294672

Self-replicative RNA vaccines elicit protection against influenza A virus, respiratory syncytial virus, and a tickborne encephalitis virus.

M N Fleeton1, M Chen, P Berglund, G Rhodes, S E Parker, M Murphy, G J Atkins, P Liljeström.   

Abstract

In genetic vaccination, recipients are immunized with antigen-encoding nucleic acid, usually DNA. This study addressed the possibility of using the recombinant alpha virus RNA molecule, which replicates in the cytoplasm of transfected cells, as a novel approach for genetic vaccination. Mice were immunized with recombinant Semliki Forest virus RNA-encoding envelope proteins from one of 3 viruses: influenza A virus, a tickborne flavivirus (louping ill virus), or respiratory syncytial virus (RSV). Serologic analyses showed that antigen-specific antibody responses were elicited. IgG isotyping indicated that predominantly Th1 type immune responses were induced after immunization with RSV F protein-encoding RNA, which is relevant for protection against RSV infection. Challenge infection showed that RNA immunization had elicited significant levels of protection against the 3 model virus diseases.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11294672     DOI: 10.1086/319857

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  45 in total

1.  Kunjin virus replicon vaccine vectors induce protective CD8+ T-cell immunity.

Authors:  Itaru Anraku; Tracey J Harvey; Richard Linedale; Joy Gardner; David Harrich; Andreas Suhrbier; Alexander A Khromykh
Journal:  J Virol       Date:  2002-04       Impact factor: 5.103

2.  Humoral and cellular immune response to RNA immunization with flavivirus replicons derived from tick-borne encephalitis virus.

Authors:  Judith H Aberle; Stephan W Aberle; Regina M Kofler; Christian W Mandl
Journal:  J Virol       Date:  2005-12       Impact factor: 5.103

3.  Protection of mice and poultry from lethal H5N1 avian influenza virus through adenovirus-based immunization.

Authors:  Wentao Gao; Adam C Soloff; Xiuhua Lu; Angela Montecalvo; Doan C Nguyen; Yumi Matsuoka; Paul D Robbins; David E Swayne; Ruben O Donis; Jacqueline M Katz; Simon M Barratt-Boyes; Andrea Gambotto
Journal:  J Virol       Date:  2006-02       Impact factor: 5.103

Review 4.  mRNA as a Transformative Technology for Vaccine Development to Control Infectious Diseases.

Authors:  Giulietta Maruggi; Cuiling Zhang; Junwei Li; Jeffrey B Ulmer; Dong Yu
Journal:  Mol Ther       Date:  2019-02-07       Impact factor: 11.454

5.  Induction of an IFN-Mediated Antiviral Response by a Self-Amplifying RNA Vaccine: Implications for Vaccine Design.

Authors:  Timothy Pepini; Anne-Marie Pulichino; Thomas Carsillo; Alicia L Carlson; Farid Sari-Sarraf; Katrin Ramsauer; Jason C Debasitis; Giulietta Maruggi; Gillis R Otten; Andrew J Geall; Dong Yu; Jeffrey B Ulmer; Carlo Iavarone
Journal:  J Immunol       Date:  2017-04-17       Impact factor: 5.422

6.  Nonviral delivery of self-amplifying RNA vaccines.

Authors:  Andrew J Geall; Ayush Verma; Gillis R Otten; Christine A Shaw; Armin Hekele; Kaustuv Banerjee; Yen Cu; Clayton W Beard; Luis A Brito; Thomas Krucker; Derek T O'Hagan; Manmohan Singh; Peter W Mason; Nicholas M Valiante; Philip R Dormitzer; Susan W Barnett; Rino Rappuoli; Jeffrey B Ulmer; Christian W Mandl
Journal:  Proc Natl Acad Sci U S A       Date:  2012-08-20       Impact factor: 11.205

Review 7.  mRNA-based therapeutics--developing a new class of drugs.

Authors:  Ugur Sahin; Katalin Karikó; Özlem Türeci
Journal:  Nat Rev Drug Discov       Date:  2014-09-19       Impact factor: 84.694

Review 8.  A development that may evolve into a revolution in medicine: mRNA as the basis for novel, nucleotide-based vaccines and drugs.

Authors:  Karl-Josef Kallen; Andreas Theß
Journal:  Ther Adv Vaccines       Date:  2014-01

Review 9.  mRNA vaccines - a new era in vaccinology.

Authors:  Norbert Pardi; Michael J Hogan; Frederick W Porter; Drew Weissman
Journal:  Nat Rev Drug Discov       Date:  2018-01-12       Impact factor: 84.694

10.  Biochemical and immunogenic characterization of soluble human immunodeficiency virus type 1 envelope glycoprotein trimers expressed by semliki forest virus.

Authors:  Mattias N E Forsell; Yuxing Li; Maria Sundbäck; Krisha Svehla; Peter Liljeström; John R Mascola; Richard Wyatt; Gunilla B Karlsson Hedestam
Journal:  J Virol       Date:  2005-09       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.